Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Current Assets (2022 - 2025)

Gossamer Bio's Current Assets history spans 4 years, with the latest figure at $167.6 million for Q4 2025.

  • For Q4 2025, Current Assets fell 45.9% year-over-year to $167.6 million; the TTM value through Dec 2025 reached $167.6 million, down 45.9%, while the annual FY2025 figure was $167.6 million, 45.9% down from the prior year.
  • Current Assets reached $167.6 million in Q4 2025 per GOSS's latest filing, down from $204.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $370.9 million in Q2 2024 to a low of $167.6 million in Q4 2025.
  • Average Current Assets over 4 years is $267.7 million, with a median of $268.7 million recorded in 2022.
  • Peak YoY movement for Current Assets: skyrocketed 113.93% in 2024, then crashed 45.9% in 2025.
  • A 4-year view of Current Assets shows it stood at $261.9 million in 2022, then increased by 17.05% to $306.5 million in 2023, then rose by 1.1% to $309.9 million in 2024, then plummeted by 45.9% to $167.6 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Current Assets are $167.6 million (Q4 2025), $204.0 million (Q3 2025), and $235.9 million (Q2 2025).